Wave Life Sciences presents preclinical data on WVE-007, a potential treatment for obesity that aims to drive fat loss while preserving muscle mass with once or twice annual dosing. In preclinical models, INHBE GalNAc-siRNA led to positive metabolic improvements, including adipocyte shrinkage and improved insulin sensitivity. When added to semaglutide, WVE-007 doubled weight loss in mice and prevented weight regain upon cessation of semaglutide. The ongoing INLIGHT clinical study showed positive target engagement with dose-dependent decreases in Activin E observed one month post-single dose of WVE-007, supporting its potential for metabolic improvement.

Wave Life Sciences is a biotechnology company focused on RNA medicines to transform human health. WVE-007 is designed to reduce fat while preserving lean mass, targeting INHBE mRNA to induce fat loss without impacting muscle mass. The company’s approach aims to make meaningful improvements in cardiometabolic health, with potential for once or twice yearly dosing. The ongoing INLIGHT clinical trial has shown significant dose-dependent reductions in Activin E levels, supporting the potential of WVE-007 for sustainable weight loss. Wave is committed to advancing innovative therapies to address obesity and other health conditions.

Read more at GlobeNewswire: Wave Life Sciences to Present Preclinical Data Supporting